La Jolla Limited Withdraws Its Marketing Authorisation Application For Riquent To Treat Lupus Nuphritis
Thu, 19 Oct 2006 12:00 AM EST
... The European Medicines Agency has been formally notified by La Jolla Limited of its decision to withdraw its application for a centralised marketing authorisation for the medicinal product Riquent (abetimus sodium). [click link for full article] ...
Related Topics
- Lupus
- Lupus Anticoagulant
- Systemic Lupus Erythematosus
- Tolterodine
- Yoga
- Lupus Nephritis
- Clinical Assessment Software Application
- Phenylephrine and Guaifenesin ER Tablets
- Guaifenesin and Potassium Guaiacolsulfonate
- Scleroderma
- Hepatitis
- Phenylephrine and Guaifenesin Capsules
- Rue
- Myopia
- Pseudoephedrine and Guaifenesin ER
- Propranolol
- Systemic Lupus Erythematosus/sle
- Diltiazem ER
- Pseudoephedrine and Guaifenesin
- Systemic Lupus

Not Signed In -


